Skip to content
Tarsus Pharmaceuticals
-
Tarsus Pharmaceuticals to acquire Alkeus in US$800M deal to expand ophthalmology pipeline
The centerpiece of the deal is gildeuretinol, formerly known as ALK-001, a once-daily oral therapy under development for Stargardt disease, a rare inherited retinal disorder.